Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice
暂无分享,去创建一个
K. To | Jian-Piao Cai | Lin-Lei Chen | Cuiting Luo | Honglin Chen | K. Yuen | H. Chu | Shuofeng Yuan | K. Kok | D. Jin | A. J. Zhang | F. Yin | Hehe Cao | Yuting Han | Xiaojuan Zhang | J. F. Chan | Kun Wang | Zhiwei Chen
[1] K. To,et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines , 2022, The Lancet Microbe.
[2] Haiwei Zhang,et al. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response , 2022, Frontiers in Immunology.
[3] K. To,et al. Evolution and Control of COVID-19 Epidemic in Hong Kong , 2022, Viruses.
[4] S. Malaivijitnond,et al. A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques , 2022, Frontiers in Plant Science.
[5] Shibo Jiang,et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses , 2022, Nature Reviews Immunology.
[6] Jie Zhou,et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines , 2022, Journal of medical virology.
[7] Tao Li,et al. An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants , 2022, Signal Transduction and Targeted Therapy.
[8] C. Ke,et al. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants , 2022, Vaccines.
[9] Jian-Piao Cai,et al. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2 , 2022, Cell Reports Medicine.
[10] K. To,et al. Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong , 2022, Nature Communications.
[11] K. To,et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters , 2022, Science.
[12] D. Lung,et al. Decreased Antibiotic Consumption Coincided with Reduction in Bacteremia Caused by Bacterial Species with Respiratory Transmission Potential during the COVID-19 Pandemic , 2022, Antibiotics.
[13] M. Davenport,et al. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? , 2022, Nature Reviews Immunology.
[14] O. Tsang,et al. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines , 2022, eBioMedicine.
[15] Wanbo Tai,et al. Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant , 2022, bioRxiv.
[16] K. To,et al. Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2 , 2022, The Lancet Microbe.
[17] Jie Zhou,et al. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant , 2022, Viruses.
[18] Paul J. Birrell,et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines , 2022, Nature Medicine.
[19] Liyuan Liu,et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.
[20] L. Poon,et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.
[21] K. To,et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.
[22] O. Tsang,et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.
[23] K. To,et al. Emerging SARS-CoV-2 variants expand species tropism to murines , 2021, EBioMedicine.
[24] J. Yee,et al. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 , 2021, Vaccine.
[25] Wenbin Zhao,et al. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 , 2021, Viruses.
[26] K. To,et al. Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] Jun-Gu Guo,et al. Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist , 2021, Journal of medicinal chemistry.
[28] M. Beltramello,et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.
[29] R. W. Yung,et al. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results. , 2021, Hong Kong medical journal = Xianggang yi xue za zhi.
[30] Jian-Piao Cai,et al. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity , 2021, Science Advances.
[31] Yan Li,et al. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice , 2021, Cellular & molecular immunology.
[32] Ronald A. Li,et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 , 2021, Nature.
[33] K. To,et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic , 2021, Emerging microbes & infections.
[34] D. Qu,et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response , 2020, Signal Transduction and Targeted Therapy.
[35] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[36] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[37] Shibo Jiang,et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.
[38] Shibo Jiang,et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity , 2009, Virology.
[39] C. Alving,et al. Human Immunodeficiency Virus Type 1 Gag p24 Alters the Composition of Immunoproteasomes and Affects Antigen Presentation , 2009, Journal of Virology.
[40] J. Ravetch,et al. Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.
[41] Shibo Jiang,et al. Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.
[42] M. Lotze,et al. Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells , 2002, The Journal of experimental medicine.